ACHE and Alzheimer disease: According to the present results, medium-dose and high-dose OMO groups exhibited a reduced AChE activity in the hippocampus and cortex of AD model rats and an increase in Ach content, suggesting that OMO could protect the cholinergic system in AD model rats.